drugset / Trial / NCT01488266
Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder
RandomizedParallel-groupSingle-blindTreatment
Summary
The objective of this study is to compare the efficacy and safety of aripiprazole as adjunctive therapy versus switching to different class of antidepressants for treating major depressive disorder partially or minimally responsive to ongoing antidepressant treatment.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-01
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 2.5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 5 mg | — |
| Comparator | Bupropion XL | Unknown | — | — |
| Comparator | Duloxetine | Small molecule | — | — |
| Comparator | Escitalopram | Small molecule | — | — |
| Comparator | Fluoxetine | Small molecule | — | — |
| Comparator | Milnacipran | Other / unclassified | — | — |
| Comparator | Mirtazapine | Other / unclassified | — | — |
| Comparator | Paroxetine | Small molecule | — | — |
| Comparator | Sertraline | Small molecule | — | — |
| Comparator | Venlafaxine | Small molecule | — | — |